FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

BACKGROUND. With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landsca...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempner, Samuel J., Madison, Russell, Pujara, Vivek, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Kim, Seung Tae, Maron, Steven B., Dayyani, Farshid, Catenacci, Daniel V.T., Lee, Jeeyun, Chao, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853122/
https://www.ncbi.nlm.nih.gov/pubmed/31249137
http://dx.doi.org/10.1634/theoncologist.2019-0121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853122/
https://www.ncbi.nlm.nih.gov/pubmed/31249137
http://dx.doi.org/10.1634/theoncologist.2019-0121

Ejemplares similares